Papatheodoridis G, Kapatais A, Sinakos E, Elefsiniotis I, Goulis J, Deutsch M, Vlachogiannakos J, Dalekos G, Koskinas J, Karatapanis S, et al. Platelets represent an independent predictor of sustained virological response (SVR) in patients with advanced chronic hepatitis C (CHC) treated with current direct acting antiviral (s)(DAA). HERACLIS: Hellenic multicenter real-life cohort study. Journal of Hepatology. 2017;66:S502.

Dalekos G, Vlachogiannakos J, Manesis EK, Goulis I, Mimidis K, Oikonomopoulou M, Ioannidou P, Kourikou A, Gatselis NK, Papageorgiou M-V, et al. Regression of liver stiffness following therapy with direct acting antiviral (s) in chronic hepatitis C patients. Results from HERACLIS: a Hellenic multicenter real-life cohort clinical study. In: HEPATOLOGY. Vol. 66. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA; 2017. pp. 619A–619A.

Vlachogiannakos J, Manolakopoulos S, Samonakis DN, Koskinas J, Papageorgiou M-V, Ketikoglou I, Oikonomopoulou M, Elefsiniotis IS, Goulis I, Vasileiadis TG, et al. Efficacy and safety of treatment with direct acting antiviral (s) in Chronic Hepatitis C (CHC) patients with compensated advanced liver disease and signs of portal hypertension. HERACLIS: a Hellenic multicenter real-life cohort clinical study. In: HEPATOLOGY. Vol. 66. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA; 2017. pp. 813A–814A.

Manolakopoulos S, Akriviadis E, Vlachogiannakos J, Papageorgiou M-V, Kapatais A, Oikonomopoulou M, Vasileiadis TG, Manesis EK, Karatapanis S, Deutsch M, et al. The impact of direct acting antivirals (DAAs) in patients with decompensated liver disease (DLD) due to chronic hepatitis C (CHC). heraclis-a multicenter greek real world study. In: Hepatology. Vol. 66. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA; 2017. pp. 838A–839A.

Papatheodoridis G, Manolakopoulos S, Kapatais A, Sinakos E, Elefsiniotis I, Goulis J, Deutsch M, Vlachogiannakos J, Dalekos G, Koskinas J, et al. Predictors of sustained virological response (SVR) in patients with advanced chronic hepatitis C (CHC) treated with current direct acting antiviral (s)(DAA). Heraclis: Hellenic multicenter real-life cohort study. Gastroenterology. 2017;152:S1093.

Goulis I, Elefsiniotis I, Karatapanis S, Koskinas J, Ioannidou P, Manolakopoulos S, Vlachogiannakos J, Oikonomopoulou M, Samonakis DN, Manesis EK, et al. High efficacy of the currently recommended regimens of 2 Direct Acting Antivirals (DAAs)+/-Ribavirin (R) in HCV genotype 4 (GT4) patients (pts) with advanced fibrosis or cirrhosis in HERACLIS real world cohort. In: HEPATOLOGY. Vol. 66. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA; 2017. pp. 815A–816A.

Voulgaris T, Vlachogiannakos J, Ioannidou P, Papageorgiou M-V, Zampeli E, Karagiannakis D, Georgiou A, Papazoglou A, Karamanolis G, Papatheodoridis GV. Adherence to follow-up and treatment recommendations in Greek and immigrant patients with chronic hepatitis B in Greece. European journal of gastroenterology & hepatology. 2017;29:264–270.

Papatheodoridis GV, Koskinas J, Goulis I, Sinakos E, Dalekos G, Kapatais A, Oikonomopoulou M, Vlachogiannakos J, Elefsiniotis IS, Deutsch M, et al. Changes in the use of direct acting antiviral (s)(DAA) in the treatment of chronic hepatitis C (CHC) patients in clinical practice. HERACLIS: a Hellenic multicenter real-life cohort clinical study. In: Hepatology. Vol. 66. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA; 2017. pp. 603A–604A.